Industrial Transformation Research Hubs - Grant ID: IH120100021
Funder
Australian Research Council
Funding Amount
$2,500,000.00
Summary
Pathways to market: transforming food industry futures through improved sensing, provenance and choice. Pathways to market: transforming food industry futures through improved sensing, provenance and choice. This Research Hub aims to transform the Australian food industry by demonstrating how new knowledge on food production and consumption generated through novel sensing technologies and advanced modelling techniques can be implemented in smart applications to power competitiveness, sustainabil ....Pathways to market: transforming food industry futures through improved sensing, provenance and choice. Pathways to market: transforming food industry futures through improved sensing, provenance and choice. This Research Hub aims to transform the Australian food industry by demonstrating how new knowledge on food production and consumption generated through novel sensing technologies and advanced modelling techniques can be implemented in smart applications to power competitiveness, sustainability and innovation in food value chains.Read moreRead less
ADAM Metalloprotease Inhibition For Treatment Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$770,925.00
Summary
Colorectal cancer (CRC) causes over 4000 deaths/year, typically from developing drug resistance and spreading to other organs (metastasis). These processes involve tumour cells called cancer stem cells (CSCs), which rely on specific cell surface proteins for survival and function. We are developing antibodies against one of these type of proteins, to test in mouse models of CRC. These already show promise in targeting CSCs and inhibiting drug-resistance and metastasis in mice.
Mechanisms Of Glucocorticoid Resistance In Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$547,970.00
Summary
Glucocorticoids are extremely active drugs used in the treatment of childhood acute lymphoblastic leukaemia (ALL), yet a proportion of patients respond poorly to therapy and exhibit resistance at relapse. Clinically relevant mechanisms of glucocorticoid resistance are poorly understood, principally due to lack of appropriate experimental models. This project will reveal novel mechanisms of drug resistance in childhood leukaemia and lead to novel therapeutic strategies to improve outcome.